This article is more than 5 years old. Information may no longer be current.

Intracorneal inlay approved to treat presbyopia in Korea

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — The Korean Food and Drug Administration has approved the use of the Kamra intracorneal inlay to treat presbyopia, AcuFocus announced in a news release.

The small-aperture inlay allows only central light rays to reach the retina through a 1.6-mm opening, allowing patients to better see near and intermediate objects while maintaining distance vision, according to the release.

The Kamra has been implanted in more than 11,000 patients and is available in 35 countries globally, the release said. It has received a CE mark for use in the European Union and is being studied in the United States under the U.S. Food and Drug Administration’s investigational device exemption rules.

“We are extremely thrilled to be able to offer this advanced vision correction technology in Korea,” Ed Peterson, AcuFocus president and CEO, said in the release.

Woo Jeon Medical will distribute the inlay in Korea.